Search results
- www.ncbi.nlm.nih.gov
- › Journal List
- › J Antimicrob Chemother
Nov 21, 2019 · On average, patients receiving nifurtimox suffered more events (6.2 versus 3.5, P<0.001) than those in the benznidazole group and were more at risk of suffering five or more adverse events (69% versus 35.9%, P<0.001).
- www.ncbi.nlm.nih.gov
- › …
- › PLoS Negl Trop Dis
- › v.16(5); 2022 May
May 16, 2022 · The only two treatments currently available (benznidazole, generally the first choice, and nifurtimox) date from the 1960s and are poorly tolerated. Moreover, there is much uncertainty about their indication, dosage and benefits, especially in chronically infected adult populations.
Oct 20, 2016 · Nifurtimox, developed by Bayer, is a nitrofuran antiprotozoal drug used in the treatment of Chagas disease. On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials.
Aug 23, 2022 · The only drugs with proven efficacy against Chagas disease in human trials are benznidazole and nifurtimox [ 2-4 ]. In general, benznidazole is better tolerated and so is favored by most experts as the first-line treatment for Chagas disease [ 5 ].
Nifurtimox, sold under the brand name Lampit, is a medication used to treat Chagas disease and sleeping sickness. For sleeping sickness it is used together with eflornithine in nifurtimox-eflornithine combination treatment. In Chagas disease it is a second-line option to benznidazole. It is given by mouth.
Treatment with benznidazole for chronic Chagas disease is associated with low cure rates and substantial toxicity. We aimed to compare the parasitological efficacy and safety of 3 different benznidazole regimens in adult patients with chronic Chagas disease. Methods.
Mar 13, 2023 · Uses. Side effects. Warnings. Before taking. Dosage. Interactions. What is nifurtimox? Nifurtimox is used to treat Chagas disease, a condition caused by a parasite. Chagas disease occurs most commonly in Mexico, Central America, and South America. Nifurtimox is for use in children from birth through their 17th year.
